Therapeutic benefits from the use of these drugs may also be obtained by patients with acute lymphoblastic leukemia with an IDH1/2 mutation or patients with myeloproliferative neoplasms (MPN), in which the presence of an IDH1/2 mutation may be associated with an increased risk of MPN transforming into AML due to the impaired differentiation of myeloid progenitor cells [79,83]. Here, IDH1 is linked to acute lymphoblastic leukemia.